– USA, CT – SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to its Board of Directors, bringing a significant leadership and commercial experience gained during his more than 30-year career in the pharmaceutical industry.
“Carlos’ success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage company in the coming year and we are thrilled to welcome him to our Board,” said CEO, Saqib Islam.
About Carlos Albán
Mr. Albán, who served as Vice-Chairman and CCO at AbbVie, Inc. until his retirement last year, brings over 30 years of experience in global commercial strategy and operations.
“SpringWorks has an exciting opportunity ahead to bring first- and best-in-class medicines to patients with devastating rare diseases and cancer,” said Carlos Albán. “I look forward to working with the leadership team to help them execute on their ambitious objectives and prepare to launch their first product.”
Under his leadership, AbbVie’s sales grew from $18 billion in 2013 to over $45 billion in 2020, making AbbVie the 5th largest pharmaceutical company in the world. Prior to this role, he was EVP, Commercial Operations and before AbbVie’s separation from Abbott, Mr. Albán served as AbbVie’s SVP, Proprietary Pharmaceutical Products, Global Commercial Operations. He also held several management positions at Abbott Laboratories, Inc., including SVP, International Pharmaceuticals; VP, Pharmaceuticals, Western Europe and Canada Operations; VP, Pharmaceuticals, European Operations; Regional Director for the Northern Europe area of the international pharmaceutical business; and General Manager, Portugal.
Mr. Albán received a degree in economics from the Pontificia Universidad Javeriana in Bogotá, Colombia.
About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.
For more information : https://www.springworkstx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
